1. Home
  2. UWMC vs EVO Comparison

UWMC vs EVO Comparison

Compare UWMC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UWM Holdings Corporation

UWMC

UWM Holdings Corporation

N/A

Current Price

$1.25

Market Cap

538.4M

Sector

Finance

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

N/A

Current Price

$1.59

Market Cap

568.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UWMC
EVO
Founded
1986
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
538.4M
568.6M
IPO Year
2019
2007

Fundamental Metrics

Financial Performance
Metric
UWMC
EVO
Price
$1.25
$1.59
Analyst Decision
Hold
Buy
Analyst Count
9
3
Target Price
$1.86
★ $4.49
AVG Volume (30 Days)
★ 12.6M
66.3K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
★ 23.62%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $3,160,569,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.23
$18.90
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 46.07
N/A
52 Week Low
$0.93
$1.33
52 Week High
$6.15
$3.87

Technical Indicators

Market Signals
Indicator
UWMC
EVO
Relative Strength Index (RSI) 41.47 48.34
Support Level $0.96 $1.50
Resistance Level $1.55 $1.61
Average True Range (ATR) 0.14 0.06
MACD -0.03 0.01
Stochastic Oscillator 0.74 28.13

Price Performance

Historical Comparison
UWMC
EVO

About UWMC UWM Holdings Corporation

UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: